A study evaluating the pharmacokinetics, safety, and tolerability of enzalutamide monotherapy and in combination with endocrine therapies (anastrozole, exemestane, and fulvestrant) in women with advanced breast cancer.

Trial Profile

A study evaluating the pharmacokinetics, safety, and tolerability of enzalutamide monotherapy and in combination with endocrine therapies (anastrozole, exemestane, and fulvestrant) in women with advanced breast cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Mar 2017

At a glance

  • Drugs Enzalutamide (Primary) ; Anastrozole; Exemestane; Fulvestrant
  • Indications Breast cancer
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
  • Sponsors Astellas Pharma; Medivation
  • Most Recent Events

    • 14 Mar 2017 New trial record
    • 09 Mar 2017 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top